Clinical trial
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
NCT00642616 is registered in ClinicalTrials.gov with Mannkind Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
- Lead sponsor
- Mannkind Corporation
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- March 31, 2009
- Completion date
- November 30, 2014
- Enrollment
- 34 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.
asthma, moderate chronic obstructive pulmonary disease, type 1 diabetes mellitus, type 2 diabetes mellitus